IOL Chemicals
IOL Chemicals Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: fundraise.
The short version
FY27 revenue growth guidance: 15% to 20% - FY28 revenue growth plan: Approximately 15% to 20% - EBITDA margin for FY27 expected in range of 14% to 15%, with potential slight improvement in FY28 (1 FY27 Revenue Growth Guidance: 15% to 20% increase expected.
From IOL Chemicals's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY27 revenue growth guidance: 15% to 20%
- FY28 revenue growth plan: Approximately 15% to 20%
- EBITDA margin for FY27 expected in range of 14% to 15%, with potential slight improvement in FY28 (15% to 17%)
- Growth driven by better capacity utilization, improved product mix, operational efficiencies, and increased exports
- Continued expansion in non-ibuprofen API portfolio to support broad-based growth
- Targeting non-ibuprofen products to contribute around 50%-55% of API segment by FY29
- Export contribution expected to be around 25% to 30% of revenue, targeting ~30% in near term
- New capacities and backward integration projects underway but major expansions expected post FY27
- Sustained growth visibility for the year with reasonable order book visibility and demand expected to remain strong
Profitability & Margins
See what IOL Chemicals said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans a capex of approximately INR 200-250 crores per year.
- Around 60% of the annual capex is directed towards expansion and new product developments.
- The remaining 40% of capex is for infrastructure improvements, enhancing efficiencies, and cost reduction.
- The company has a 101-acre land parcel for future expansion; statutory permissions are underway.
- New projects on the 101-acre land are expected beyond the current fiscal year (not in FY27).
- R&D is active with ongoing projects; they will share more when proof-of-concepts are ready.
- Investments in high-end analytical machines (XRD, LCMS, GCMS) have been made to support quality and impurity analysis.
- Strategic focus on building a diversified API portfolio with backward integration and operational efficiencies.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what IOL Chemicals said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has reasonable visibility into its order book for the coming quarter, providing confidence in the overall guidance for the year.
- Strong demand and healthy order inflow are expected to sustain growth this year.
- Export agreements include quantities with specific customers, and some variability quarter-to-quarter in dispatches can cause minor fluctuations in export numbers.
- No specific quantitative details on the total order book size or pending orders were disclosed during the call.
- Company maintains a disciplined approach to capital allocation and investments based on long-term returns, implying ongoing order inflow aligned with capacity expansions and product mix improvements.
IOL Chemicals — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹619 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What IOL Chemicals & Pharmaceuticals Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…
Frequently Asked Questions
What were IOL Chemicals Q1 FY27 results?
FY27 revenue growth guidance: 15% to 20% - FY28 revenue growth plan: Approximately 15% to 20% - EBITDA margin for FY27 expected in range of 14% to 15%, with potential slight improvement in FY28 (1 FY27 Revenue Growth Guidance: 15% to 20% increase expected.
What is IOL Chemicals share price analysis?
IOL Chemicals currently shows a below-average growth signal. The stock trades at a P/E of 28.2 with a market cap of ₹4,976 Cr. Investors should review the full earnings analysis for detailed insights.
Is IOL Chemicals planning capital expenditure?
The company plans a capex of approximately INR 200-250 crores per year.
Keep IOL Chemicals on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.